Sellas, Life

Sellas Life Sciences: Full Green Shoe Lifts Placement to $172.5 Million as REGAL Data Draw the Analyst Upgrade

Published on 11/21/2026 at 15:21 | Editorial boerse-global.de
Sellas closed a $172.5M stock sale at $13 per share after the greenshoe was fully exercised; shares fell 8.1% as REGAL trial data showed a 41% death risk cut.
Sellas Life Sciences Illustration mit AI erstellt.

Sellas Life Sciences has closed the books on an equity raise that grew larger than first advertised, and the market's immediate verdict was a share price decline of 8.1%. The company confirmed the completed placement on Friday, two days after pricing it and one day after Maxim Group lifted its price target on the stock.

The financing ultimately comprised 13,269,231 shares priced at $13.00 apiece, generating gross proceeds of $172.5 million. That figure is struck before underwriting discounts, commissions and other expenses are deducted. When Sellas first announced the offering on 17 November, it was targeting gross proceeds of $150.0 million.

Underwriters Exercise the Option in Full

The step-up from the initial target traces to the greenshoe. At pricing on Wednesday, the company had sized a smaller base deal and attached an option for the syndicate of banks to purchase additional shares. That overallotment was exercised completely at closing, which accounts for the final share count and the higher headline number.

Sellas had also guided at pricing — assuming the option was taken up in full — to net proceeds of roughly $161.8 million. That projection already factored in the underwriting discounts and commissions along with estimated additional placement costs.

Should investors sell immediately? Or is it worth buying Sellas Life Sciences?

For existing holders, the transaction cuts two ways. The balance sheet gains capital, but the ownership stake is now spread across a larger number of shares. A successful raise and a good outcome for current shareholders are not the same thing, and the distinction between gross proceeds and what actually lands in the company's coffers matters just as much.

REGAL Delivers the Clinical Case

The counterweight to the dilution question sits in the Phase 3 REGAL trial, whose positive topline results were released on Tuesday. Galinpepimut-S, or GPS, met the primary endpoint on overall survival in acute myeloid leukemia.

Sellas reported a 41% reduction in the risk of death. Median overall survival came in at 24.0 months, against 14.7 months for patients on the best available treatment.

Those numbers form the medical core of the investment case, and the capital raise does nothing to alter them. By the same token, strong trial data do not answer the question of what valuation is appropriate once new shares have been issued.

Maxim Doubles Down

Jason McCarthy of Maxim Group raised his price target to $40 from $30, keeping his buy rating intact. The upgrade followed the primary endpoint hit. It is an optimistic analyst view rather than a settled future share price.

Sellas Life Sciences at a turning point? This analysis reveals what investors need to know now.

Looking ahead, Sellas intends to hold discussions with the FDA and aims to prepare a marketing application for submission in the first half of 2027.

Weighing the two threads together is the sensible approach: the documented clinical advance on one side, the terms on which it was financed on the other. The study supplies the medical argument. The share sale shows why that argument alone does not set the market's valuation.

Ad

Sellas Life Sciences Stock: New Analysis - 21 November

Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Sellas Life Sciences analysis...

Disclaimer...
en | US81642T2096 | SELLAS | boerse | 70542783 |